- Home
- NML vs CINGW Comparison
NML vs CINGW Comparison
Compare NML & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- CINGW
- Stock Information
- Founded
- NML 2012
- CINGW N/A
- Country
- NML United States
- CINGW United States
- Employees
- NML N/A
- CINGW 13
- Industry
- NML Finance/Investors Services
- CINGW Biotechnology: Pharmaceutical Preparations
- Sector
- NML Finance
- CINGW Health Care
- Exchange
- NML Nasdaq
- CINGW Nasdaq
- Market Cap
- NML 454.4M
- CINGW N/A
- IPO Year
- NML N/A
- CINGW 2021
- Fundamental
- Price
- NML $8.21
- CINGW $0.04
- Analyst Decision
- NML
- CINGW
- Analyst Count
- NML 0
- CINGW 0
- Target Price
- NML N/A
- CINGW N/A
- AVG Volume (30 Days)
- NML 219.3K
- CINGW N/A
- Earning Date
- NML 01-01-0001
- CINGW N/A
- Dividend Yield
- NML 9.75%
- CINGW N/A
- EPS Growth
- NML N/A
- CINGW N/A
- EPS
- NML N/A
- CINGW N/A
- Revenue
- NML N/A
- CINGW N/A
- Revenue This Year
- NML N/A
- CINGW N/A
- Revenue Next Year
- NML N/A
- CINGW N/A
- P/E Ratio
- NML N/A
- CINGW N/A
- Revenue Growth
- NML N/A
- CINGW N/A
- 52 Week Low
- NML $6.09
- CINGW N/A
- 52 Week High
- NML $7.33
- CINGW N/A
- Technical
- Relative Strength Index (RSI)
- NML 38.94
- CINGW N/A
- Support Level
- NML $7.70
- CINGW N/A
- Resistance Level
- NML $8.50
- CINGW N/A
- Average True Range (ATR)
- NML 0.43
- CINGW 0.00
- MACD
- NML -0.02
- CINGW 0.00
- Stochastic Oscillator
- NML 42.06
- CINGW 0.00
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About CINGW Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.